Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Our product pipeline candidates utilize the hydrogel technology to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release dosage forms that can be tailored to produce the desired drug release profile. It is our intention to develop a product portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing. Ocular Therapeutixâs lead product candidate, DEXTENZA⢠(dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development targeting glaucoma and ocular hypertension. The Companyâs earlier stage assets include OTX-TIC, a sustained release travoprost intracameral implant targeting moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal implant for the treatment of retinal diseases. These injectable implants include OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutixâs first product, ReSureÂŽ Sealant, is approved to seal corneal incisions following cataract surgery. Source
No articles found.
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerati...
BioCardia, Inc., headquartered in San Carlos, C...
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...
G1 Therapeutics, Inc., is a clinical-stage biop...
miRagen Therapeutics, Inc., is a clinical stage biopharmaceutical company discover...
miRagen Therapeutics, Inc., is a clinical stage...
Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on...
Outlook Therapeutics is a late clinical-stage b...
Join the National Investor Network and get the latest information with your interests in mind.